Phenominer Database Results (14 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Record ID Study ID
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 30.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68718 839
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 13.3 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68731 829
DA.ACI-(D10Rat2-D10Rat29)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 1 23.0 d in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68727 839
DA.ACI-(D10Rat2-D10Rat29)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 3 14.7 d 1.44 2.5 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68719 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 7 14.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68726 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 0.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68733 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 14.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68734 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68724 839
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 1 3.0 d 0.0 0.0 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68730 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 75.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68735 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 3 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68721 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68722 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 1 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68729 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68732 829